Charles River Laboratories (NYSE: CRL) reported Q3 EPS of $0.86, $0.06 better than the analyst estimate of $0.80. Revenue for the quarter came in at $327.6 million versus the consensus estimate of $326.7 million.

Charles River Laboratories sees FY2014 EPS of $3.33-$3.38, versus prior guidance of $3.25-$3.35 and the consensus of $3.33.

For earnings history and earnings-related data on Charles River Laboratories (CRL) click here.